BM ageing: Implication for cell therapy with EPCs

Erica Rurali; Beatrice Bassetti; Gianluca Lorenzo Perrucci; Marco Zanobini; Cristina Malafronte; Felice Achilli; Elisa Gambini

doi:10.1016/j.mad.2016.04.002

BM ageing: Implication for cell therapy with EPCs

Erica Rurali, Beatrice Bassetti, Gianluca Lorenzo Perrucci, Marco Zanobini, Cristina Malafronte, Felice Achilli, Elisa Gambini

Centro Cardiologico Monzino

Research output: Contribution to journal › Article › peer-review

Abstract

The bone marrow (BM) is a well-recognized source of stem/progenitor cells for cell therapy in cardiovascular diseases (CVDs). Preclinical and clinical studies suggest that endothelial progenitor cells (EPCs) contribute to reparative process of vascular endothelium and participate in angiogenesis. As for all organs and cells across the lifespan, BM and EPCs are negatively impacted by ageing due to microenvironment modifications and EPC progressive dysfunctions. The encouraging results in terms of neovascularization observed in young animals after EPC administration were mitigated in aged patients treated for ischemic CVDs. The limited efficacy of EPC-based therapy in clinical setting might be ascribed at least partly to ageing. In this review, we comprehensively discussed the age-related changes of BM and EPCs and their implication for cardiovascular cell-therapies. Finally, we examined alternative approaches under investigation to enhance EPC potency.

Original language	English
Pages (from-to)	4-13
Number of pages	10
Journal	Mechanisms of Ageing and Development
Volume	159
DOIs	https://doi.org/10.1016/j.mad.2016.04.002
Publication status	Published - Oct 2016

Keywords

Review
Journal Article

Access to Document

10.1016/j.mad.2016.04.002

Cite this

@article{8f81596575b14e84b3131c9a5f2c06e1,

title = "BM ageing: Implication for cell therapy with EPCs",

abstract = "The bone marrow (BM) is a well-recognized source of stem/progenitor cells for cell therapy in cardiovascular diseases (CVDs). Preclinical and clinical studies suggest that endothelial progenitor cells (EPCs) contribute to reparative process of vascular endothelium and participate in angiogenesis. As for all organs and cells across the lifespan, BM and EPCs are negatively impacted by ageing due to microenvironment modifications and EPC progressive dysfunctions. The encouraging results in terms of neovascularization observed in young animals after EPC administration were mitigated in aged patients treated for ischemic CVDs. The limited efficacy of EPC-based therapy in clinical setting might be ascribed at least partly to ageing. In this review, we comprehensively discussed the age-related changes of BM and EPCs and their implication for cardiovascular cell-therapies. Finally, we examined alternative approaches under investigation to enhance EPC potency.",

keywords = "Review, Journal Article",

author = "Erica Rurali and Beatrice Bassetti and Perrucci, {Gianluca Lorenzo} and Marco Zanobini and Cristina Malafronte and Felice Achilli and Elisa Gambini",

year = "2016",

month = oct,

doi = "10.1016/j.mad.2016.04.002",

language = "English",

volume = "159",

pages = "4--13",

journal = "Mechanisms of Ageing and Development",

issn = "0047-6374",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - BM ageing

T2 - Implication for cell therapy with EPCs

AU - Rurali, Erica

AU - Bassetti, Beatrice

AU - Perrucci, Gianluca Lorenzo

AU - Zanobini, Marco

AU - Malafronte, Cristina

AU - Achilli, Felice

AU - Gambini, Elisa

PY - 2016/10

Y1 - 2016/10

N2 - The bone marrow (BM) is a well-recognized source of stem/progenitor cells for cell therapy in cardiovascular diseases (CVDs). Preclinical and clinical studies suggest that endothelial progenitor cells (EPCs) contribute to reparative process of vascular endothelium and participate in angiogenesis. As for all organs and cells across the lifespan, BM and EPCs are negatively impacted by ageing due to microenvironment modifications and EPC progressive dysfunctions. The encouraging results in terms of neovascularization observed in young animals after EPC administration were mitigated in aged patients treated for ischemic CVDs. The limited efficacy of EPC-based therapy in clinical setting might be ascribed at least partly to ageing. In this review, we comprehensively discussed the age-related changes of BM and EPCs and their implication for cardiovascular cell-therapies. Finally, we examined alternative approaches under investigation to enhance EPC potency.

AB - The bone marrow (BM) is a well-recognized source of stem/progenitor cells for cell therapy in cardiovascular diseases (CVDs). Preclinical and clinical studies suggest that endothelial progenitor cells (EPCs) contribute to reparative process of vascular endothelium and participate in angiogenesis. As for all organs and cells across the lifespan, BM and EPCs are negatively impacted by ageing due to microenvironment modifications and EPC progressive dysfunctions. The encouraging results in terms of neovascularization observed in young animals after EPC administration were mitigated in aged patients treated for ischemic CVDs. The limited efficacy of EPC-based therapy in clinical setting might be ascribed at least partly to ageing. In this review, we comprehensively discussed the age-related changes of BM and EPCs and their implication for cardiovascular cell-therapies. Finally, we examined alternative approaches under investigation to enhance EPC potency.

KW - Review

KW - Journal Article

U2 - 10.1016/j.mad.2016.04.002

DO - 10.1016/j.mad.2016.04.002

M3 - Article

C2 - 27045606

VL - 159

SP - 4

EP - 13

JO - Mechanisms of Ageing and Development

JF - Mechanisms of Ageing and Development

SN - 0047-6374

ER -

BM ageing: Implication for cell therapy with EPCs

Abstract

Keywords

Access to Document

Fingerprint

Cite this